By continuing to use the site you agree to our Privacy & Cookies policy

Your browser seems to have cookies disabled. For the best experience of this website, please enable cookies in your browser.


Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.


New drug combo licensed for BPH symptoms

A new drug combination has been licensed in the UK for the treatment of lower urinary tract symptoms in men.

The once-daily fixed-dose combination of solifenacin 6mg/tamsulosin 0.4mg (Vesomni) is licensed for moderate to severe storage symptoms – urgency, increased micturition frequency – and voiding symptoms associated with benign prostatic hyperplasia in men not adequately responding to monotherapy.

It is due to be launched by Astellas Pharma early next year.


Have your say

You must sign in to make a comment.

Related Jobs

Sign in to see the latest jobs relevant to you!